Ultragenyx stock crashed Thursday, losing almost half its value, after its experimental Angelman treatment failed in final-phase testing. Angelman syndrome causes developmental delays, balance problems and speech impairment. In the…
Κωνσταντίνος Κουτουλάκης03/09/2026
